Insulin Infusion in Neonates: Hyperglycemia Management in Preterm Babies

Introduction to Neonatal Hyperglycemia

Neonatal hyperglycemia, commonly defined as a blood glucose concentration exceeding 150 mg/dL (8.3 mmol/L) in whole blood or 180 mg/dL (10 mmol/L) in plasma, is a frequent metabolic complication in NICUs, particularly in extremely preterm infants. The incidence ranges from 40 to 80 percent in infants born before 28 weeks of gestation and approximately 20 percent in all NICU admissions. While transient mild hyperglycemia may be tolerated, persistent or severe hyperglycemia is associated with increased morbidity including osmotic diuresis, dehydration, electrolyte imbalance, increased IVH risk, and possibly increased mortality.

In Indian NICUs, hyperglycemia management follows a stepwise approach: first reducing the glucose infusion rate, then treating underlying precipitating factors such as sepsis or steroid use, and finally initiating insulin infusion when glucose remains elevated despite these measures. This article provides a detailed insulin infusion protocol for neonatal hyperglycemia management applicable to Indian NICU settings.

Pathophysiology of Neonatal Hyperglycemia

Why Preterm Neonates Are Susceptible

The pathophysiology of hyperglycemia in preterm neonates differs fundamentally from diabetes mellitus. Several interconnected mechanisms contribute to glucose dysregulation in this population.

• Persistent hepatic glucose production: Preterm neonates maintain high rates of endogenous hepatic glucose output (4 to 8 mg/kg/min) that is poorly suppressed by exogenous glucose or insulin, reflecting hepatic insulin resistance.
• Immature beta-cell function: Extremely preterm infants have reduced pancreatic beta-cell mass and impaired glucose-stimulated insulin secretion. The insulin secretory response to hyperglycemia is blunted and delayed.
• Peripheral insulin resistance: Immature insulin receptor signaling in skeletal muscle and adipose tissue limits glucose uptake even when insulin is present.
• Iatrogenic glucose loading: TPN-delivered glucose infusion rates exceeding 6 to 8 mg/kg/min commonly overwhelm the metabolic capacity of extremely preterm infants.
• Stress and illness: Sepsis, surgical stress, pain, and respiratory distress elevate cortisol and catecholamines, which increase gluconeogenesis and glycogenolysis while worsening insulin resistance.
• Medications: Dexamethasone, hydrocortisone, high-dose dopamine, and theophylline all promote hyperglycemia through various mechanisms.

Stepwise Management Approach

Step 1: Verify and Evaluate

Confirm hyperglycemia with a laboratory plasma glucose level, as point-of-care glucometers can be inaccurate at extremes and in neonates with high hematocrit. Simultaneously evaluate for precipitating causes: obtain blood cultures if sepsis is suspected, review medication list for steroids or vasopressors, verify the glucose infusion rate calculation, and check for glucose administration errors.

Step 2: Reduce Glucose Infusion Rate

Decrease the GIR by 1 to 2 mg/kg/min increments, rechecking glucose in 1 to 2 hours. The minimum GIR to maintain adequate caloric intake and prevent protein catabolism is approximately 4 mg/kg/min. Reducing GIR below this threshold to control hyperglycemia sacrifices caloric intake and is counterproductive for growth. If hyperglycemia persists at a GIR of 4 to 5 mg/kg/min, insulin should be initiated rather than further caloric restriction.

Step 3: Insulin Infusion

Insulin infusion is indicated when blood glucose exceeds 250 mg/dL despite GIR reduction, or when glucose exceeds 180 mg/dL with glycosuria causing clinically significant osmotic diuresis (urine output above 4 mL/kg/hour with urine glucose 2+ or greater).

Insulin Infusion Protocol

Preparation

1. Use only regular (soluble) human insulin. Insulin analogues (lispro, aspart, glargine) are not validated for continuous infusion in neonates.
2. Standard preparation: 5 units of regular insulin in 50 mL of 0.9 percent normal saline gives a concentration of 0.1 unit/mL.
3. Critical step - Line priming: Run 20 to 50 mL of the prepared insulin solution through the entire infusion set and discard before connecting to the patient. Insulin binds extensively to polyvinyl chloride tubing, and without adequate priming, actual insulin delivery may be 50 to 80 percent less than calculated during the initial hours.
4. Use a dedicated line on a precision syringe pump. Do not co-infuse with other medications.

Dosing and Titration

Blood Glucose	Action
> 250 mg/dL	Start at 0.05 units/kg/hour
180-250 mg/dL with glycosuria	Start at 0.02 units/kg/hour
Target: 100-180 mg/dL	Maintain current rate; gradually increase GIR
80-100 mg/dL	Reduce insulin by 50%
60-80 mg/dL	Stop insulin; increase GIR by 2 mg/kg/min
< 60 mg/dL	Stop insulin; D10% bolus 2 mL/kg; increase GIR; recheck in 30 min

Titrate in 0.01 to 0.02 units/kg/hour increments every 1 to 2 hours during the acute phase. Maximum recommended dose is 0.1 units/kg/hour. If hyperglycemia persists at maximum rates, reassess for untreated sepsis, corticosteroid use, or glucose calculation errors.

Monitoring Protocol

• Blood glucose: Every 1 hour during initiation and dose changes. Once stable in target range for 4 to 6 hours, extend to every 2 to 4 hours. Use bedside glucometers for frequent checks, with periodic laboratory confirmation. HEAMAC point-of-care glucose systems support the frequent testing required during insulin titration.
• Serum potassium: Every 6 to 12 hours. Insulin drives potassium intracellularly, and preterm neonates are already at risk of electrolyte imbalance. Supplement potassium proactively if levels trend downward.
• Urine output and glucose: Hourly urine output monitoring. Test urine glucose to track resolution of glycosuria.
• Daily weight: Resolution of osmotic diuresis may unmask fluid retention. Adjust total fluid intake accordingly.
• Serum sodium and osmolality: Hyperglycemia causes pseudo-hyponatremia and hyperosmolality. Monitor during correction to avoid rapid osmolality shifts.

Practical Challenges in Indian NICUs

Precision of Delivery

For a 700-gram infant at 0.02 units/kg/hour, the required insulin rate is only 0.014 units per hour. Using 0.1 unit/mL concentration, this translates to 0.14 mL/hour, which is at the accuracy limit of many syringe pumps. In government NICUs where precision syringe pumps may not be available, using a more dilute solution (0.05 units/mL) doubles the flow rate, improving delivery accuracy. However, this requires careful labeling and staff education to prevent dosing errors.

Glucose Monitoring Limitations

Point-of-care glucometers widely used in Indian NICUs may have significant inaccuracy at extremes of glucose and in the presence of high neonatal hematocrit. Laboratory confirmation of values below 60 mg/dL or above 300 mg/dL is essential. Continuous glucose monitoring systems are being studied in neonates and may improve glycemic management in Indian NICUs in the future.

Special Considerations

Hyperglycemia During Sepsis

Sepsis-associated hyperglycemia reflects insulin resistance driven by pro-inflammatory cytokines and counter-regulatory hormones. Treating the underlying infection is the most important intervention. Insulin requirements typically decrease as sepsis resolves. Concurrent treatment with antibiotics and supportive care must not be delayed for glucose management.

Steroid-Induced Hyperglycemia

Dexamethasone for BPD commonly causes hyperglycemia within the first 24 to 48 hours of treatment. Insulin infusion may be required for the duration of the steroid course. Plan for insulin when initiating dexamethasone in extremely preterm infants, and increase glucose monitoring frequency from the first dose.

Weaning and Discontinuation

As the underlying cause resolves, insulin requirements decrease. The weaning approach involves reducing insulin by 0.01 units/kg/hour every 4 to 6 hours while simultaneously increasing GIR toward the caloric goal of 10 to 12 mg/kg/min. Discontinue insulin when glucose remains stable at adequate GIR without insulin. Continue glucose monitoring every 4 to 6 hours for 24 hours post-discontinuation to detect rebound hyperglycemia.

Evidence: The NIRTURE Trial

The NIRTURE (Neonatal Insulin Replacement Therapy in Europe) trial randomized extremely preterm infants to early continuous insulin infusion (maintaining glucose 72 to 144 mg/dL) versus standard care. The insulin group had higher rates of hypoglycemia without improvement in survival, growth, or neurodevelopment. This landmark trial argues against routine insulin use purely to normalize blood glucose and supports the current selective approach of treating only symptomatic or severe hyperglycemia.

Conclusion

Insulin infusion is an essential tool for managing persistent hyperglycemia in preterm neonates when reduction of glucose infusion rate is insufficient. Safe implementation requires meticulous preparation with adequate line priming, delivery via precision syringe pumps, frequent glucose monitoring, and vigilant potassium surveillance. In Indian NICUs at all levels, standardized protocols with clear titration guidelines and hypoglycemia safety nets are critical for preventing both the morbidity of persistent hyperglycemia and the potentially devastating consequences of iatrogenic hypoglycemia.